The news is directly about BridgeBio Pharma. While the Overweight rating is maintained, the lowering of the price target could potentially have a negative impact on the stock's price in the short term. However, the impact is not clear cut as the Overweight rating indicates that the analyst still believes the stock will outperform the market.